MX2022007161A - Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad. - Google Patents
Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad.Info
- Publication number
- MX2022007161A MX2022007161A MX2022007161A MX2022007161A MX2022007161A MX 2022007161 A MX2022007161 A MX 2022007161A MX 2022007161 A MX2022007161 A MX 2022007161A MX 2022007161 A MX2022007161 A MX 2022007161A MX 2022007161 A MX2022007161 A MX 2022007161A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage form
- biologically active
- coating layer
- active ingredient
- disease
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000011247 coating layer Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 239000010410 layer Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940126409 proton pump inhibitor Drugs 0.000 abstract 1
- 239000000612 proton pump inhibitor Substances 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a una forma de dosificación, que comprende un ingrediente biológicamente activo para usarse en el tratamiento o prevención de una enfermedad en el cuerpo animal o humano, cuyo tratamiento o prevención requiera la liberación del 50% o más del ingrediente biológicamente activo en el intestino delgado dentro del intervalo de pH de 3 a 5.5, en donde la forma de dosificación comprende: a) un núcleo, que comprende el ingrediente biológicamente activo, b) una capa de revestimiento intermedio (ICL) sobre o por encima del núcleo, que comprende un agente alcalino, y c) una capa de revestimiento entérico (ECL) sobre o por encima de la capa de revestimiento intermedio que comprende un polímero entérico, en donde la relación del agente alcalino con respecto al polímero entérico en la forma de dosificación es del 5 al 95% cuando se calcula por medio de la fórmula: (ver Fórmula) en donde se exceptúan los ingredientes biológicamente activos que son inhibidores de la bomba de protones que pertenecen a la clase de compuestos de benzimidazol sustituido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201941051259 | 2019-12-11 | ||
PCT/EP2020/075962 WO2021115650A1 (en) | 2019-12-11 | 2020-09-17 | Dosage form for use in treating or preventing of a disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022007161A true MX2022007161A (es) | 2022-07-12 |
Family
ID=72560602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022007161A MX2022007161A (es) | 2019-12-11 | 2020-09-17 | Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad. |
Country Status (12)
Country | Link |
---|---|
US (1) | US11730708B2 (es) |
EP (1) | EP4072532B1 (es) |
JP (1) | JP2023505882A (es) |
KR (1) | KR20220113698A (es) |
CN (1) | CN114786652A (es) |
BR (1) | BR112022011055A2 (es) |
CA (1) | CA3160869A1 (es) |
IL (1) | IL293648A (es) |
MX (1) | MX2022007161A (es) |
PL (1) | PL4072532T3 (es) |
SI (1) | SI4072532T1 (es) |
WO (1) | WO2021115650A1 (es) |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
US6500457B1 (en) | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
CA2558535A1 (en) | 2004-03-03 | 2005-10-06 | Teva Pharmaceutical Industries Ltd. | A stable pharmaceutical composition comprising an acid labile drug |
DE102005032806A1 (de) | 2005-07-12 | 2007-01-18 | Röhm Gmbh | Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten |
ES2759626T3 (es) | 2007-05-07 | 2020-05-11 | Evonik Operations Gmbh | Formas farmacéuticas sólidas que comprenden un recubrimiento entérico con liberación acelerada del fármaco |
BRPI0821985A2 (pt) | 2008-01-10 | 2015-06-23 | Evonik Roehm Gmbh | Preparacao farmacêutica ou nutracêutica revestida tendo liberação de substância ativa controlada |
CN101877971A (zh) | 2008-01-10 | 2010-11-03 | 赢创罗姆有限公司 | 具有活性物质在结肠中增强的释放的包衣药物或营养制剂 |
CA2733787C (en) * | 2008-08-15 | 2016-09-06 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders |
WO2011140446A2 (en) | 2010-05-06 | 2011-11-10 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations |
DE102010052847A1 (de) | 2010-11-29 | 2012-05-31 | Temmler Werke Gmbh | Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung |
CN102626398A (zh) | 2012-04-18 | 2012-08-08 | 上海腾瑞制药有限公司 | 一种泮托拉唑钠肠溶片及其制备方法 |
US9452143B2 (en) | 2012-07-12 | 2016-09-27 | Novus International, Inc. | Matrix and layer compositions for protection of bioactives |
KR101973235B1 (ko) | 2012-08-27 | 2019-08-16 | 에보니크 룀 게엠베하 | 에탄올의 영향에 대해 지속 방출 특성 및 내성을 갖는 제약 또는 기능식품 조성물 |
WO2014136494A1 (ja) | 2013-03-08 | 2014-09-12 | 富士フイルム株式会社 | 腸溶性細粒及び医薬組成物 |
AU2013404367B2 (en) | 2013-10-29 | 2020-02-27 | Tillotts Pharma Ag | A delayed release drug formulation |
CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
SI3233066T1 (sl) * | 2014-12-17 | 2022-02-28 | Empros Pharma AB, c/o BTR, | Sestavek s prirejenim sproščanjem, ki vsebuje orlistat in akarbozo za zdravljenje prekomerne teže in povezanih metaboličnih motenj |
EP3117824A1 (en) * | 2015-07-17 | 2017-01-18 | BE Pharbel Manufacturing | Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form |
PL3324948T3 (pl) * | 2015-07-17 | 2023-06-26 | BE Pharbel Manufacturing | Wielowarstwowe mikrocząstki uwalniające związek farmaceutycznie aktywny w płynnej postaci dawkowania |
CN105640915A (zh) * | 2016-03-02 | 2016-06-08 | 吉林修正药业新药开发有限公司 | 一种雷贝拉唑钠肠溶片及其制备工艺 |
EP3484449B1 (en) * | 2016-04-19 | 2020-11-04 | CONARIS research institute AG | Shellac microcapsule formulations and compositions for topical intestinal delivery of vitamin b3 |
WO2020229178A1 (en) | 2019-05-15 | 2020-11-19 | Evonik Operations Gmbh | Process for preparing filled hard-shell capsules with (meth)acrylate copolymer based coatings with a capsule-filling machine |
JP2023505883A (ja) | 2019-12-11 | 2023-02-13 | エボニック オペレーションズ ゲーエムベーハー | 病気の治療又は予防において使用するための剤形 |
CN114828833A (zh) | 2019-12-11 | 2022-07-29 | 赢创运营有限公司 | 包含碱剂和肠溶包衣层的剂型 |
-
2020
- 2020-09-17 MX MX2022007161A patent/MX2022007161A/es unknown
- 2020-09-17 SI SI202030404T patent/SI4072532T1/sl unknown
- 2020-09-17 WO PCT/EP2020/075962 patent/WO2021115650A1/en unknown
- 2020-09-17 IL IL293648A patent/IL293648A/en unknown
- 2020-09-17 CA CA3160869A patent/CA3160869A1/en active Granted
- 2020-09-17 PL PL20774964.9T patent/PL4072532T3/pl unknown
- 2020-09-17 KR KR1020227019198A patent/KR20220113698A/ko unknown
- 2020-09-17 JP JP2022535763A patent/JP2023505882A/ja active Pending
- 2020-09-17 BR BR112022011055A patent/BR112022011055A2/pt unknown
- 2020-09-17 CN CN202080085419.5A patent/CN114786652A/zh active Pending
- 2020-09-17 US US17/757,043 patent/US11730708B2/en active Active
- 2020-09-17 EP EP20774964.9A patent/EP4072532B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3160869A1 (en) | 2021-06-17 |
KR20220113698A (ko) | 2022-08-16 |
EP4072532A1 (en) | 2022-10-19 |
US11730708B2 (en) | 2023-08-22 |
WO2021115650A1 (en) | 2021-06-17 |
BR112022011055A2 (pt) | 2022-08-23 |
PL4072532T3 (pl) | 2024-06-10 |
CN114786652A (zh) | 2022-07-22 |
IL293648A (en) | 2022-08-01 |
EP4072532B1 (en) | 2024-01-24 |
US20230012981A1 (en) | 2023-01-19 |
SI4072532T1 (sl) | 2024-05-31 |
JP2023505882A (ja) | 2023-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022007160A (es) | Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad. | |
BR112018002045B1 (pt) | Método não terapêutico para melhorar o crescimento de um animal, uso de um complexo de fe(iii) para fabricar um produto alimentício, e, produto alimentício contendo dito complexo | |
WO2005072308A3 (en) | Cgrp receptor antagonists | |
NZ592673A (en) | Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease | |
MX2022007162A (es) | Forma de dosificacion que comprende un agente alcalino y una capa de revestimiento enterico. | |
IN2014MN00139A (es) | ||
EA200970933A1 (ru) | Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста | |
WO2008085484A3 (en) | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid | |
EA201390353A1 (ru) | Производное пиразолохинолина | |
BR112022009861A2 (pt) | Derivado de cicloalquil ureia | |
MX2018011974A (es) | Composicion para controlar microsporidia en peces y metodo para controlar microsporidia en peces utilizando la misma. | |
JP2011507859A5 (es) | ||
MX2023013536A (es) | Metodos para tratar la depresion y la ansiedad. | |
MX2022007161A (es) | Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad. | |
MX2021002277A (es) | Composicion farmaceutica que comprende agente antiplaquetario e inhibidor de la secrecion de acido gastrico. | |
MX2023001457A (es) | Agente para tratar la miopia, prevenir la miopia y/o suprimir la progresion de la miopia. | |
PL2165704T3 (pl) | Zastosowanie alweryny w leczeniu dolegliwości skórnych | |
JP2017532369A5 (es) | ||
MX2009011819A (es) | Formulaciones de aminoacido n-halogenado. | |
GB2413764B8 (en) | Anthelmintic compostion | |
MX2020007817A (es) | Prevención y tratamiento del trastorno del sueño. | |
MX2017011697A (es) | Articulo sanitario que comprende una composicion de control de ph, y metodo para su produccion. | |
MY160963A (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction | |
EA202193211A1 (ru) | Лечение синуклеопатий | |
RU2010144554A (ru) | Средство для предотвращения и/или лечения сосудистых заболеваний |